New anticoagulants in ischemic heart disease

Presse Medicale

Volumn 34, Issue 18, 2005, Pages 1325-1329

  Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NEW DRUG; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBIN; WARFARIN; XIMELAGATRAN;

ANGIOCARDIOGRAPHY; ANGIOPLASTY; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY STENT; DOSE RESPONSE; FIBRINOLYSIS; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; REVIEW; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 27544439050     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84181-8     Document Type: Short Survey

References (34)

1. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
2. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Kostering H, Oster H, Leitz K. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979;2:354-63.
3. Serruys PW, Arnold AE, Brower RW, de Bono DP, Bokslag M, Lubsen J et al. Effect of continued rt-PA administration on the residual stenosis after initially successful recanalization in acute myocardial infarction. A quantitative coronary angiography study of a randomized trial. Eur Heart J 1987; 8: 1172-81.
4. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137-40.
5. Willich SN, Linderer T, Wegschneider K, Leizorovicz A, Alamercery I, Schröder R. Increased morning incidence of myocardial infarction in the ISAM studv: absence with prior β-adrenergic blockade. ISAM Study Group. Circulation 1989;80:853-8.
6. Andreotti F, Kluft C, Davies GJ, Huisman LG, de Bart AC, Maseri A. Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1. Am J Cardiol 1991;68:1295-9.
7. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
8. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847-60,
9. Verheugt FWA, Meijer A, Lagrand WK, Van Eenige MJ. Reocclusion, the f upside of coronary thrombolysis. J Am Coll Cardiol 1996;27:766-73.
10. Giugliano RP, McCabe CH, Antman EM, Cannon CP, Van de Werf F, Wilcox RG et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001;141:742-50.
11. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA et al. Management of acute myocardial infarction in patients presenting with ST segment-elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
12. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Hb investigators. N Engl J Med 1996;335:775-82.
13. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina and revascularisation procedures in patients with acute myocardial ischemia without ST-elevation: randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999;353:429-38.
14. White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-63.
15. Wallentin L, Dellborg DM, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol 2001;24(3Suppl):112-14.
16. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L et al. Randomized comparison of enoxaparin, a low molecular weight heparin, with unfractionated heparin adjunctive to tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-52.
17. Simoons M, Krzeminska-Pakula M, Alonso A, Goodman S, Kali A, Loos U et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23:1282-90.
18. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE-study. Eur Heart J 2001;22:1716-24.
19. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.
20. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR et al. Efficacy and safety of tenecteplase in combination with the low-molecular weight heparin enoxaparin, or unfractionated heparin in the pre-hospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-42.
21. Bahit MC, Topol EJ, Califf RM, Armstrong PW, Criger DA, Hasselblad V et al. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use ot Strategies To Open occluded arteries in acute coronary syndromes. J Am Coll Cardiol 2001;37:1001-7.
22. Brouwer MA, Verheugt FWA. Oral anticoagation in acute coronary syndromes. Circulation 2002;105:1270-4.
23. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003;41(4Suppl S):62S-69S.
24. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end-points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994;8-9:81-8.
25. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet 1997;350:3-89-96.
26. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators J Am Coll Cardiol 2001;37:475-84.
27. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P et al. for the Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group. Department of veteran affairs cooperative studies program clinical trial comparing combined warfarin and asprin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP study. Circulation 2002;105:557-63.
28. Brouwer MA, Van den Bergh PJ, Vromans RPJW, Aengevaeren WR, Veen G, Luijten HE et al. Aspirin plus coumadin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002;106:659-65.
29. Van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.
30. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
31. Williams MJ, Morison IM, Parker JH, Stewart RH. Progression of the culprit leasion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 1997;30:364-9.
32. Herlitz J, Holm J, Peterson M, Karlson B, Evander M, Erhardt L. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. Eur Heart J 2004;25:232-9.
33. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97.
34. Verheugt FWA. Can we pull the plug on warfarin in atrial fibrillation? Lancet 2003;362:1686-7.